Skip to Content
Upcoming Webinar

Vorasidenib: the First and Only mIDH1/2 Inhibitor for Patients With Grade 2 mIDH Glioma

Date: December 5, 2024 | 12:00 AM

Explore how vorasidenib, the first mIDH1/2 inhibitor for grade 2 gliomas with IDH1/2 mutations, is transforming treatment.

Dr. Tresa McGranahan, MD, PhD from Scripps Clinic Medical Group will cover:

  • The impact of IDH1 and IDH2 mutations
  • The role of molecular profiling in treatment decisions
  • Vorasidenib’s mechanism of action, clinical efficacy, and safety for patients with grade 2 astrocytoma or oligodendroglioma